# Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

> **NCT05253911** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 49 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** TUKYSA®

## Key facts

- **NCT ID:** NCT05253911
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-21
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05253911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05253911, "Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05253911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*